Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated (LGND) Stock Overview
Explore Ligand Pharmaceuticals Incorporated’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
3.6B
P/E Ratio
73.43
EPS (TTM)
$2.26
ROE
0.06%
LGND Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Ligand Pharmaceuticals Incorporated (LGND) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 40.65, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $233.62.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 73.43 and a market capitalization of 3.6B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.